Lacidipine Dr. Reddy's Laboratories (Uk)

Lacidipine, the active ingredient in Lacidipine Dr. Reddy's Laboratories (Uk), is a calcium channel blocker presented as an oral tablet for oral use. It is prescribed to lower elevated blood pressure in adults with hypertension. It is indicated for the management of essential hypertension and may be used as part of combination therapy when monotherapy is insufficient.

GNH USA supplies Lacidipine Dr. Reddy's Laboratories (Uk) as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Lacidipine is used to treat hypertension by relaxing vascular smooth muscle and reducing peripheral resistance.

Essential hypertension: lowers systolic and diastolic blood pressure. Isolated systolic hypertension: reduces pulse pressure and improves arterial compliance. Mild to moderate hypertension: achieves target blood pressure levels as part of therapy. Resistant hypertension (as adjunct): provides additional reduction when other agents are insufficient. Hypertension with cardiovascular risk: helps lower overall risk by controlling blood pressure.

Lacidipine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate headache may occur. - Flushing: transient facial flushing. - Peripheral edema: swelling of ankles or feet. - Dizziness: light‑headedness, especially after standing.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Hepatic dysfunction: signs of liver injury such as jaundice.

When prescribing Lacidipine, clinicians should consider several precautionary measures.

- Monitor blood pressure: check regularly to ensure therapeutic effect. - Use caution in hepatic impairment: dose may need adjustment. - Avoid abrupt discontinuation: tapering reduces rebound hypertension risk. - Assess for concomitant antihypertensives: risk of additive hypotension. - Caution in elderly patients: increased sensitivity to blood pressure changes. - Store at ambient temperature: keep in original container, protect from moisture.

Lacidipine interacts with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can markedly increase Lacidipine plasma levels. - Grapefruit juice: may elevate drug concentration leading to excessive hypotension. - Concurrent use with other potent vasodilators: risk of severe hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Diuretics: may enhance antihypertensive effect, requiring blood pressure monitoring. - Beta‑blockers: combined therapy may increase risk of bradycardia and hypotension.